CompletedPhase 2NCT02433795
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Studying MALT lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seoul National University Hospital
- Principal Investigator
- Dae Seog Heo, MD, PhDSeoul National University Hospital
- Intervention
- bendamustine plus rituximab(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2019
Study locations (11)
- Chonbuk National University Hospital, Jeonju, Jeollabuk-do, South Korea
- Hallym University Medical Center, Anyang-si, South Korea
- Chungnam National University, Daejeon, South Korea
- Gachon University Gil Medical Center, Incheon, South Korea
- Gyeongsang National University Hospital, Jinju, South Korea
- Seoul National University Bundang Hospital, Seongnam, South Korea
- Inje Universit, Seoul, South Korea
- Korea Cancer Center Hospital, Seoul, South Korea
- Seoul National University Boramae Hospital, Seoul, South Korea
- Seoul National University Hospital, Seoul, South Korea
- The Catholic University of Korea, Seoul, South Korea
Collaborators
Gyeongsang National University Hospital · Korea Cancer Center Hospital · Seoul National University Boramae Hospital · Hallym University Medical Center · Inje University · Gangnam Severance Hospital · Chonbuk National University Hospital · Chungnam National University · The Catholic University of Korea · Wonju Severance Christian Hospital · Gachon University Gil Medical Center · Seoul National University Bundang Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02433795 on ClinicalTrials.govOther trials for MALT lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaGottfried von Keudell, MD PhD
- RECRUITINGPHASE2NCT07441993Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07372365Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.The First Affiliated Hospital of Soochow University
- RECRUITINGNCT06712459Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone LymphomaInternational Extranodal Lymphoma Study Group (IELSG)
- RECRUITINGPHASE2NCT06796998Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)Izidore Lossos, MD
- ACTIVE NOT RECRUITINGPHASE2NCT07480863Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGPHASE2NCT07247383Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE2NCT07208981Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLThe First Affiliated Hospital with Nanjing Medical University